an affiliate of
     
We Need Your help as a 50-State Network Advocate!
Now is your time to be heard
Join the 50-State Network here
The 50-State Network is a grassroots advocacy organization comprised of patients like you. We are working to share the patient perspective, which is crucial in the State and Federal health policy and regulatory arenas. Patients need a voice in all conversations that relate to our access to treatment, safety, or the quality of our care. This community is made up of patients living with diverse chronic illnesses, including rheumatoid arthritis, lupus, and psoriasis, and the people who care about them. The 50-State Network is about transforming pain into purpose, empowering those that may feel victimized by disease. Our focus is on repurposing the energy of frustration, despair, and helplessness into positive mobilization, action, and fair representation to benefit all of us. Our formula, which we offer to our fellow patients and their loved ones, is to take lemons and make lemonade.
GHLF in the news
The Rheumatology network logo
Editorial: CreakyJoints Urges Uninterrupted Supply of Biosimilars

The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.

Advocates in the news
IMG_1438 cropped
Salem resident testifies on biosimilar substitution bill

Salem resident Joni Johnston testified to the Missouri General Assembly’s House Emerging Issues Committee Jan. 20.

Letters and Testimony
imagejpeg_0
GHLF – CreakyJoints FDA Public Meeting Statement for CT-P13

The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Inc.